Translational Proteomics Leverage AYOXXA's LUNARIS multiplex platform for translational proteomics across basic and clinical R&D, highlighting opportunities to partner with pharma/biotech customers needing high-quality, reproducible biomarker analysis at picogram sample scales.

Ophthalmology Focus Target ophthalmology and eye research institutes with LUNARIS based detection kits and chemokine/molecular profiling kits, presenting a streamlined path from discovery to translational readouts in ocular disease programs.

Clinical Readiness Position LUNARIS as an integrated, scalable solution with built-in quality control and data management to accelerate clinical biomarker validation, enabling collaborations with translational science groups and contract research organizations.

Strategic Partnerships Explore collaboration opportunities stemming from past partnerships (e.g., SERI) to expand geographic reach and access eye research networks, while offering co-developed kits and assay services to accelerate market penetration.

Growth Enablers Highlight the potential for revenue growth through kit portfolio expansion (chemokine, T cell characterization, Th17) and reader/instrument upgrades, targeting mid-size biotechs and niche pharma segments with budget-conscious translational proteomics programs.